CPIX vs AMRX

For growth investors, Cumberland Pharmaceuticals Inc.

(CPIX) is the stronger pick with 17. 6% revenue growth year-over-year, versus 8. 0% for Amneal Pharmaceuticals, Inc. (AMRX). Amneal Pharmaceuticals, Inc. (AMRX) offers the better valuation at 62. 4x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Amneal Pharmaceuticals, Inc. (AMRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amneal Pharmaceuticals, Inc.

(AMRX) delivered a total return of +163. 8%, compared to +62. 7% for Cumberland Pharmaceuticals Inc. (CPIX). Over 10 years, the gap is even starker: CPIX returned -8. 1% versus AMRX's -54. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cumberland Pharmaceuticals Inc.

(CPIX) is the lower-risk stock at 1. 09β versus Amneal Pharmaceuticals, Inc. 's 1. 17β — meaning AMRX is approximately 8% more volatile than CPIX relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 41% for Cumberland Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cumberland Pharmaceuticals Inc.

(CPIX) is pulling ahead at 17. 6% versus 8. 0% for Amneal Pharmaceuticals, Inc. (AMRX). On earnings-per-share growth, the picture is similar: Amneal Pharmaceuticals, Inc. grew EPS 157. 9% year-over-year, compared to 58. 7% for Cumberland Pharmaceuticals Inc.. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amneal Pharmaceuticals, Inc.

(AMRX) is the more profitable company, earning 2. 4% net margin versus -6. 4% for Cumberland Pharmaceuticals Inc. — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMRX leads at -0. 2% versus -6. 3% for CPIX. At the gross margin level — before operating expenses — CPIX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cumberland Pharmaceuticals Inc.

(CPIX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Both have compounded well over 10 years (CPIX: -8. 1%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CPIX is a small-cap high-growth stock; AMRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.